BioNTech (NASDAQ:BNTX) Now Covered by Svb Leerink

Svb Leerink assumed coverage on shares of BioNTech (NASDAQ:BNTX) in a report published on Monday morning, Briefing.com Automated Import reports. The firm issued an outperform rating on the stock.

Several other equities analysts have also commented on the company. Canaccord Genuity started coverage on BioNTech in a research note on Monday. They set a buy rating and a $22.00 price target on the stock. JPMorgan Chase & Co. started coverage on BioNTech in a research note on Monday. They set an overweight rating and a $23.00 price target on the stock. Bank of America started coverage on BioNTech in a research note on Monday. They set a buy rating and a $21.00 price target on the stock. Finally, UBS Group started coverage on BioNTech in a research note on Monday. They set a buy rating and a $21.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average target price of $22.17.

Shares of BioNTech stock traded up $0.45 during trading on Monday, hitting $18.87. 78,100 shares of the stock traded hands, compared to its average volume of 321,229. BioNTech has a 52-week low of $12.52 and a 52-week high of $21.99.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer.

Read More: Roth IRA

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.